Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2 -Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
- Hee Kyung Ahn
- , Sung Hoon Sim
- , Koung Jin Suh
- , Min Hwan Kim
- , Jae Ho Jeong
- , Ji Yeon Kim
- , Dae Won Lee
- , Jin Hee Ahn
- , Heejung Chae
- , Kyung Hun Lee
- , Jee Hyun Kim
- , Keun Seok Lee
- , Joo Hyuk Sohn
- , Yoon La Choi
- , Seock Ah Im
- , Kyung Hae Jung
- , Yeon Hee Park
- Gachon University
- National Cancer Center Korea
- Seoul National University
- Yonsei University
- University of Ulsan
- Sungkyunkwan University
Research output: Contribution to journal › Article › peer-review
50
Link opens in a new tab
Scopus
citations